Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Kovack Advisors Inc.

Kovack Advisors Inc. raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,672 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,783 shares during the period. Jazz Pharmaceuticals accounts for about 0.7% of Kovack Advisors Inc.'s holdings, making the stock its 28th biggest position. Kovack Advisors Inc. owned 0.09% of Jazz Pharmaceuticals worth $6,425,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its holdings in shares of Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after acquiring an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC increased its stake in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after buying an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at about $33,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Analysts Set New Price Targets

JAZZ has been the topic of several recent research reports. Needham & Company LLC restated a "buy" rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, November 7th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Royal Bank of Canada raised their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating for the company in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a report on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $175.00.

Jazz Pharmaceuticals Trading Down 0.1 %

Shares of Jazz Pharmaceuticals stock traded down $0.09 during trading hours on Wednesday, reaching $127.65. The stock had a trading volume of 811,763 shares, compared to its average volume of 677,377. The firm has a 50 day simple moving average of $111.61 and a two-hundred day simple moving average of $110.18. The firm has a market capitalization of $7.72 billion, a price-to-earnings ratio of 17.98, a P/E/G ratio of 1.07 and a beta of 0.57. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at $4,078,453.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company's stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 over the last ninety days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.